Polaris Partners — 2015 Investments
11 investments dated 2015 · listed companies and verified rows first · show all
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)Tillman Gerngross(Director)Arnon Rosenthal PhD(Founder)in
BoardCarl Gordon(Director)
Board seatTerry McGuire· per SEC Form D · $32.3M raise · filed Sep 2015
Co-investorsForesite CapitalMission Bay CapitalMission BiocapitalMRL Ventures FundSV Health Investors
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Paul Schimmel(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Frederic Chereau(Executive Officer)
BoardAkkaraju Srinivas(Non-Management Director)
Board seatAmir Nashat· per SEC Form D · $76.3M raise · filed Apr 2015
Co-investorsCardinal PartnersEcoR1 CapitalSofinnova VenturesDomain PartnersSamsara BioCapital
Fate Therapeutics develops clinical-stage cell therapy drug candidates for autoimmune diseases and cancer, using an induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered cell products.
BiotechHealthtechSan Diego, US
Christian Weyer(Executive Officer, Director)J. Scott Wolchko(Executive Officer)Daniel Shoemaker(Executive Officer)
BoardJohn Mendlein(Director)William Rastetter(Director)
Board seatAmir Nashat· per SEC Form D · $10.3M raise · filed Aug 2016
Co-investorsSanofi VenturesVenrock
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)
BoardKristina Burow(Director)inKatrine Bosley(Director)Michael Gilman(Director)
Board seatAmir Nashat· per SEC Form D · $40M raise · filed Jan 2016
Co-investorsAisling CapitalARCH Venture PartnersEcoR1 Capital
On-demand alcohol delivery platform providing consumers with a better way to shop for wine and spirits
Sherborn, US
Justin Robinson(Executive Officer)inNicholas Rellas(Executive Officer, Director)James Cory Rellas(Executive Officer)
BoardWalt Doyle(Director)Barkley Stuart(Director)
Board seatPat Kinsel· per SEC Form D · $34.6M raise · filed Dec 2018
Co-investorsAvenir Growth CapitalEdmonton UnlimitedWinklevoss CapitalAvenirSuffolk Equity PartnersTiger Global Management
Iora Health was a primary care company focused on value-based care for Medicare-eligible seniors, operating clinics with a team-based model including health coaches.
Digital HealthHealthtechWellness & FitnessSan Francisco, US
RUSHIKA FERNANDOPULLE(Executive Officer, Director)CHRISTOPHER J. MCKOWN(Executive Officer, Director)DAVID FIELDING(Executive Officer)ALEXANDER PACKARD(Executive Officer)DAVID JUDGE(Executive Officer)
BoardSTEPHEN KNIGHT(Director)in
Board seatTerry McGuire· per SEC Form D · $48.2M raise · filed Sep 2015
Co-investors.406 VenturesDag VenturesF-Prime CapitalFlare Capital PartnersGV (Google Ventures)Lifeforce Capital+5 more
Kallyope is a drug discovery and development company working on therapeutic agents for neurological and metabolic diseases.
BiotechDeep TechHealthtechMedical DevicesNew York City, US
Tom Maniatis(Director)Nancy Thornberry(Executive Officer, Director)Kenneth Clark(Executive Officer)
BoardJoshua Wolfe(Director)inTim Kutzkey(Director)
Board seatTerry McGuire· per SEC Form D · $44M raise · filed Oct 2016
Co-investorsDns CapitalIllumina VenturesLux CapitalThe Column Group
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)in
Board seatAmir Nashat· per SEC Form D · $37.8M raise · filed Nov 2016
Co-investorsage1EcoR1 CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+2 more
HealthtechLexington, US
Robert S. Langer(Director)Michael J. Cima(Director)David Neafus(Executive Officer)Cheryl R. Blanchard(Executive Officer, Director)Robert Farra(Executive Officer)
Board seatTerrance G. McGuire· per SEC Form D · $18.6M raise · filed Jun 2015
Co-investorsKendall Capital Partners
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)George Vlasuk(Executive Officer, Director)
BoardJean-Francois Formela(Director)inMarian Nakada(Director)
Board seatAlan Crane· per SEC Form D · $25M raise · filed Mar 2018
Co-investorsage1Brace PharmaSanofi VenturesAtlas VentureSR One Capital Management
BiotechLexington, US
Robert Clarke(Chief Executive Officer and Member of the Board of Directors)David Hava(Chief Scientific Officer)David Edwards(Director)
BoardSteven Gillis(Director)David Maki(Director)
Board seatTerrance McGuire· per SEC Form D · $34.1M raise · filed Jun 2015
Co-investors5AM Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.